REAL-WORLD DATA ON IMPACT OF ESLICARBAZEPINE ACETATE ON QOL. Issue 12 (15th November 2016)

• Record Type: Journal Article
• Authors: McMurray, Rob; Kerr, Michael; Sousa, Rui; Holtkamp, Martin
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 87:Issue 12(2016)
• Page Start: e1
• Page End: e1
• Publication Date: 2016-11-15
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2016-315106.86
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Purpose: To assess impact of eslicarbazepine acetate (ESL) on patient-rated quality of life (QOL) and clinician-rated global improvement in patients included in the EPOS (Eslicarbazepine acetate in Partial-Onset Seizures) study. Method: EPOS was an open-label, prospective study which included adults with uncontrolled partial-onset seizures receiving antiepileptic monotherapy, whose clinician had previously and independently decided to initiate ESL add-on therapy. QOL was assessed (at baseline and after 3 and 6 months) using the QOL in Epilepsy Inventory-10 (QOLIE-10). Global improvement was assessed (after 3 and 6 months) using the Clinical Global Impression-Global Improvement scale (CGI-GI). Results: Overall, 219 patients were included in the study (mean age 45.9 years; 57.5% male). Complete QOLIE-10 data were available for 109 patients. Mean QOLIE-10 score decreased from 2.9 (n=128) at baseline to 2.4 (−14.6%; n=114) after 3 months and 2.1 (−20.8%; n=109) after 6 months. The majority of patients were 'much improved' or 'very much improved' on the CGI-GI after 3 months ('much improved', 49.8%; 'very much improved', 14.9%; n=211) and 6 months ('much improved', 41.7%; 'very much improved', 33.9%'; n=192). Conclusion: In this real-world study, ESL as add-on to antiepileptic monotherapy provided beneficial effects on patient-rated QOL and clinician-rated global improvement. Supported by Eisai.